Cargando…

A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer

PURPOSE: To assess the therapeutic value of biomarker-guided chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). METHODS: Eighty-five NSCLC patients at stage IIIb or IV were divided into two groups based on the feasibility of biomarker analysis. Group A included patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qiang, Zhu, Xiaoli, Zhang, Li, Sun, Siqing, Huang, Jing, Lin, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175041/ https://www.ncbi.nlm.nih.gov/pubmed/25119181 http://dx.doi.org/10.1007/s00280-014-2513-x

Ejemplares similares

Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
por: Wang, Huan, et al.
Publicado: (2014)

Erratum to: Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis
por: Wang, Huan, et al.
Publicado: (2014)

XPG is a novel biomarker of clinical outcome in advanced non-small-cell lung cancer
por: Yuli, Yi, et al.
Publicado: (2013)

Serum miR-27a is a biomarker for the prognosis of non-small cell lung cancer patients receiving chemotherapy
por: Xie, Erfu, et al.
Publicado: (2021)

ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
por: Wang, Xiyong, et al.
Publicado: (2017)

Progress in image-guided radiotherapy for the treatment of non-small cell lung cancer
por: Ren, Xiao-Cang, et al.
Publicado: (2019)

Identification of circRNA_001846 as putative non–small cell lung cancer biomarker
por: Yang, Fan, et al.
Publicado: (2021)

Oligorecurrence Non–small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography–Guided (125)I Seed Implantation vs. Second-Line Chemotherapy
por: Wang, Hao, et al.
Publicado: (2020)

The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review
por: Ning, Xiangu, et al.
Publicado: (2021)

Safety and effectiveness of localized lung resection combined with neoadjuvant chemotherapy in the treatment of stage I–II non-small cell lung cancer
por: Zhu, Bing, et al.
Publicado: (2017)

Prognostic biomarkers correlated with immune infiltration in non‐small cell lung cancer
por: Xu, Fei, et al.
Publicado: (2022)

The Evaluation of Serum Biomarkers for Non-small Cell Lung Cancer (NSCLC) Diagnosis
por: Fang, Rui, et al.
Publicado: (2018)

Implantation of computed tomography-guided Iodine-125 seeds in combination with chemotherapy for the treatment of stage III non-small cell lung cancer
por: Huo, Xiaodong, et al.
Publicado: (2017)

Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy
por: Bergot, Emmanuel, et al.
Publicado: (2013)

Chemotherapy of non-small cell lung cancer.
por: Williams, C. J.
Publicado: (1989)

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study
por: Hu, Xingsheng, et al.
Publicado: (2015)

Potential Prospective Biomarkers for Non-small Cell Lung Cancer: Mini-Chromosome Maintenance Proteins
por: Huang, Chen, et al.
Publicado: (2021)

Katanin P60: a potential biomarker for lymph node metastasis and prognosis for non-small cell lung cancer
por: Wang, Lei, et al.
Publicado: (2020)

A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy
por: Dong, Shuang, et al.
Publicado: (2022)

Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
por: Omersa, Daniel, et al.
Publicado: (2016)

Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark
por: Dalvi, Tapashi, et al.
Publicado: (2023)

m(6)A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer
por: Zhang, Zhihui, et al.
Publicado: (2021)

miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy
por: Wang, Fang, et al.
Publicado: (2015)

Adjuvant chemotherapy of non-small-cell lung cancer
por: Douillard, J.Y.
Publicado: (2013)

Adjuvant Chemotherapy of Non-Small Cell Lung Cancer
por: Pirker, Robert
Publicado: (2012)

Development and Validation of a DeepSurv Nomogram to Predict Survival Outcomes and Guide Personalized Adjuvant Chemotherapy in Non-Small Cell Lung Cancer
por: Yang, Bin, et al.
Publicado: (2022)

Long non-coding RNAs in non-small cell lung cancer as biomarkers and therapeutic targets
por: Chen, Jing, et al.
Publicado: (2014)

PEG‐rhG‐CSF for prophylaxis of neutropenia after chemotherapy in patients with non–small cell lung cancer: A multicenter, prospective, randomized study
por: Sun, Xu‐Sheng, et al.
Publicado: (2022)

Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China
por: Zhang, Mengdie, et al.
Publicado: (2023)

Newly diagnosed non‐small cell lung cancer with interstitial lung abnormality: Prevalence, characteristics, and prognosis
por: Zhu, Min, et al.
Publicado: (2023)

Whole Brain Radiotherapy Plus Concurrent Chemotherapy in Non-Small Cell Lung Cancer Patients with Brain Metastases: A Meta-Analysis
por: Qin, Hong, et al.
Publicado: (2014)

miR-486 as an unfavorable prognostic biomarker for patients with non-small cell lung cancer
por: Gao, Zhao-Jia, et al.
Publicado: (2020)

Plasma Soluble Podoplanin as a Biomarker of Hypercoagulability and Cellular Immunity Status in Patients With Non-small Cell Lung Cancer
por: Zhang, Qian, et al.
Publicado: (2023)

Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study
por: Zhou, Tao, et al.
Publicado: (2023)

Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer
por: Wu, Peng, et al.
Publicado: (2022)

Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies
por: Gao, Ruo-Lin, et al.
Publicado: (2022)

VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review
por: Liu, Lian, et al.
Publicado: (2019)

Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment
por: Zhou, Jianya, et al.
Publicado: (2018)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
por: Zhang, Yun, et al.
Publicado: (2021)

PRKCDBP Methylation is a Potential and Promising Candidate Biomarker for Non-small Cell Lung Cancer
por: LI, Jing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p6q06du4fpd8nffl9967cb10ue